The American pharmaceutical and biotechnology company's dose is the fifth vaccine to receive emergency validation from the WHO.
The World Health Organisation has approved the Moderna Covid-19 vaccine (mRNA 1273) for emergency use.
The American pharmaceutical and biotechnology company's dose is the fifth vaccine to receive emergency validation from the WHO. The WHO's emergency use listing is based on the assessment of late phase II and phase III clinical trial data and substantial additional data on safety, efficacy, quality and a risk management plan.
The vaccine was reviewed by WHO's Strategic Advisory Group of Experts on Immunization (SAGE). On January 25, 2021, the SAGE had made an interim recommendation clearing the vaccine for use for all age groups 18 and above.
The US Food and Drug Administration had granted emergency use authorization for the Moderna vaccine on December 18, 2020. The European Medicines Agency too okayed the use of Moderna vaccine throughout the European Union on January 6m 2021.
The Moderna vaccine (mRNA 1273) has an efficacy of 94.1%.
According to WHO, although the vaccine is provided as a frozen suspension at –25 ºC to –15 ºC in a multidose vial, vials can be stored refrigerated at 2–8 °C for up to 30 days before the withdrawal of the first dose. That means that ultra-cold chain equipment may not always be necessary to deploy the vaccine.
NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona
Last Updated May 1, 2021, 9:33 AM IST